Dr. ZHU Zhongyuan, aged 5 4, is our founder, chairman of the Board, executive Director and chief executive officer of our Company. He also holds directorships and managerial positions across our subsidiaries. Dr. ZHU was re-designated as our executive Director on August 12, 2024. He is primarily responsible for strategic vision, corporate management and business planning of our Group.

Dr. ZHU is a sophisticated and resourceful veteran in China’s biotech industry with strong scientific and business acumen. He brings in over 20 years of experience bridging the realms of biotech entrepreneurship and venture investment. Dr. ZHU has been instrumental in investing in and incubating a number of notable emerging biotech companies, including CStone Pharmaceuticals (2616.HK), RemeGen (9995.HK), Gan & Lee Pharmaceuticals (603087. SH), and BGI Genomics (300676. SH). Throughout his career, Dr. ZHU has focused on value creation, and has established a reputation of driving growth and innovation, navigating marketdynamics while managing operational risks. He developed company building acumen at two leading biotech venture investment firms, including 6 Dimensions Capital, where he served as a Partner from 2018 to 2019, and Wuxi Healthcare Ventures, where he also held the position of Partner from 2015 to 2017. Prior to these roles, Dr. ZHU held various senior roles at Mingxin Capital, SIG Asia Investment Fund, Greenwoods Investment and HighLight Capital, from 2008 to 2015.

In addition, Dr. ZHU held multiple non-executive directorships at various portfolio companies, including a non-executive director of Phoenix Healthcare Group Co., Ltd. (currently known as China Resources Medical Holdings Company Limited (1515. HK)), from September 2013 to July 2014, and a non-executive director of CStone Pharmaceuticals (2616. HK), from April 2016 to August 2018. In 2006, he was the senior director at Shanghai Genomics, Inc., which was later acquired by GNI Group Ltd, an integrated multinational biopharma.

Dr. ZHU obtained a bachelor’s degree in molecular biology from Nankai University in the PRC in July 1992, a Ph.D. in biomedical science from the University of Massachusetts at Worcester in the United States in June 2001, and an MBA from the University of California at Berkeley in the United States in December 2005. In July 2020, Dr. ZHU was honored with “14th Jinji Lake Leading Scientific Talent of Suzhou Industrial Park” by the Suzhou Industrial Park Administrative Committee .

Dr. Yang QIU joined the Group in 2021. She was appointed as chief scientific officer (CSO) and the general manager of Duality U.S. She is mainly responsible for directing the R&D, providing scientific insights and leadership, and progressing key assets of the Group.

Dr. QIU brings over 20 years of global leadership experience in the biopharmaceutical industry, with a demonstrated track record of success in drug discovery, translational medicine and early clinical development. Prior to joining our Group, Dr. Qiu worked for GSK China, lastly as director, leading the progress of early drug discovery, Johnson & Johnson China, as Director of Biomarker Research, responsible for the design and delivery of multiple biomarkers studies in clinical development programs of the company's oncology portfolio and Daiichi Sankyo Inc., responsible for the development of global translational medicine and early development strategy for ADC programs.

Dr. QIU obtained a master’s degree and a Ph.D. from University of Texas at Austin in the United States, respectively.

Dr. Hua Mu serves as the Global Chief Medical Officer (CMO) at Duality Biologics. He previously served as Chief Executive Officer/Acting Chief Medical Officer/China Head at Zenas BioPharma (NASDAQ: ZBIO). Prior to Zenas, Dr. Mu was a co-founder of Overland Pharmaceuticals and served as Interim CEO and CMO, while also serving as Venture Partner at Hillhouse Capital. 

 Dr. Mu also served as senior executives at Simcere Pharmaceutical Group, WuXi AppTec, and Hutchison MediPharma after he returned to China in 2010. Prior to that, he worked for Genentech, Biogen Idec, Abraxis Bioscience, and Roche Pharmaceuticals in the US. With extensive experience in building and leading R&D organizations and international collaborations, Dr. Mu has a proven track record of successful development and approval of new drugs in China and around the globe. He participated in and led the development of approximately 30 innovative drug candidates in multiple therapeutic areas, including 10 drugs approved in the US/globe  or in China, with majority in oncology. 

 Dr. Mu conducted translational and clinical research at the University of California, San Francisco and the University of Washington Schools of Medicine before joining industry in 1999. He received his PhD degree in Epidemiology from the University of California at Berkeley and his MD degree from West China University of Medical Sciences.

Ms. Wei GU is the chief medical officer. She is mainly responsible for leading clinical development team and developing clinical development strategies of the Group.

Ms. GU possesses more than 10 years of experience in clinical trial management and research. Her career began as a resident physician and then an attending physician at Huadong Hospital Affiliated to Fudan University since 1996. Ms. GU worked for Quintiles Medical Development (Shanghai) and Boehringer Ingelheim International (Shanghai). She served as a director of clinical development at AstraZeneca Global R&D (China) in 2010, mainly responsible for operations of clinical programs in mainland China and Hong Kong. Ms. GU served as a senior director at Sino-American Shanghai Squibb Pharmaceuticals Ltd. in 2012. Ms. GU served as vice president at Shanghai Greenvalley Pharma and Shanghai Haihe Biopharma respectively. Later from 2018 to 2022, Ms. GU worked for Shanghai Baili Jiasheng Pharma with positions including head of clinical development and regulatory and China chief medical officer.

Ms. GU obtained a bachelor’s degree in clinical medicine and a master’s degree in internal medicine from Shanghai Medical University (currently known as Shanghai Medical College, Fudan University, respectively.

Mr. WANG has 20 years of experience in Wall Street healthcare research and banking, all based in New York. Worked as a member of a top-ranked pharmaceutical equity research team at J.P. Morgan and UBS

Has advised many leading Asian pharmaceutical and healthcare companies on business strategy and cross-border transactions during almost 15-year stint at Mizuho Bank. Previously worked as a research scientist at Schering-Plough Corporation in New Jersey

Graduated top of his class from NYU Stern School of Business with four merit awards. M.Sc. degree in Biochemistry from The University of British Columbia and B.Sc. in Microbiology from Nankai University

Dr. Haiqing Hua has rich experience in the field of drug discovery and development in both multi-national company and domestic pharma company; Primary inventor of multiple novel peptide, antibody and ADC molecules; Direct contribution to IND/NDA approval of biopharmaceuticals in US or China

Previously as Head of Biopharmaceuticals and Competitive Intelligence at Hansoh Pharma, leading preclinical discovery and development (nonclinical and CMC), and regulatory affairs of peptide, antibody and ADC programs. Previously as Principal Investigator at Eli Lilly, leading drug screening platform, GPCR agonist/antagonist and antibody discovery programs

Postdoc in stem cell and gene therapy at Columbia University Medical Center (New York), PhD in neurodegenerative diseases from University of Zurich (Switzerland), and BS from Tsinghua University in China